InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,982.00
(
-0.06%
)
US TECH 100
20,452.40
(
-0.18%
)
Dow Jones
43,958.83
(
0.00%
)
Brent Oil
72.47
(
0.84%
)
Bitcoin
88,096.81
(
-2.72%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120721
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 7087

Saturday, 01/19/2008 12:06:40 AM

Saturday, January 19, 2008 12:06:40 AM

Post# of 19309
>as to the short duration, the protocol in the published study is 4 days of infusion and the Leo study is 5 days -- is one extra day likely to be that important?<

Probably not. What is more consequential than the number of days of treatment is whether a trial’s protocol allows for antithrombin dose adjustment based on a patient’s antithrombin level during treatment. Leo’s trial presumably permits such adjustment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up